Frédéric Delolme

Dr. Frédéric Delolme

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
SNSophie Nolivos
Sophie Nolivos
JCJulien Cayron
Julien Cayron
ADAnnick Dedieu
Annick Dedieu
APAdeline Page
Adeline Page
FDFrédéric Delolme
Frédéric Delolme
CLChristian Lesterlin
Christian Lesterlin
A race against time: Clinically relevant antimicrobial resistance is largely spread via plasmids that disperse among bacteria during conjugation. How quickly can a resistance gene be expressed after transfer? In susceptible bacterial cells, tetracycline should inhibit protein synthesis, including from the plasmid-transferred resistance gene tetA . Unexpectedly, Nolivos et al. found that TetA can be expressed despite the presence of tetracycline (see the Perspective by Povolo and Ackermann). Immediately after plasmid transfer into a cell, TetA synthesis starts because its repressor is slow to be expressed. In addition, the ubiquitous xenobiotic efflux pump AcrAB-TolC buys time for TetA translation by keeping tetracycline concentration below toxic levels. Science , this issue p. 778 ; see also p. 737

7 July 2020 in Science Signaling
Verified
Journal Article
Closed access
PDF file
CACyril Anastasi
Cyril Anastasi
PRPatricia Rousselle
Patricia Rousselle
MTMaya Talantikite
Maya Talantikite
ATAgnès Tessier
Agnès Tessier
CCCaroline Cluzel
Caroline Cluzel
CMCatherine Moali
Catherine Moali
BMP-1–mediated cleavage of TSP-1 reduces cell adhesion and promotes TGF-β signaling.

8 April 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
ADAissatou Maty Diagne
Aissatou Maty Diagne
APAnaïs Pelletier
Anaïs Pelletier
CDClaire Durmort
Claire Durmort
AFAgathe Faure
Agathe Faure
KKKerstin Kanonenberg
Kerstin Kanonenberg
COCédric Orelle
Cédric Orelle
Two-component regulatory systems (TCS) are among the most widespread mechanisms that bacteria use to sense and respond to environmental changes. In the human pathogen Streptococcus pneumoniae, a total of 13 TCS have been identified and many of them have been linked to pathogenicity. Notably, TCS01 strongly contributes to pneumococcal virulence in several infection models. However, it remains one of the least studied TCS in pneumococci and its functional role is still unclear. In this study, we demonstrate that TCS01 cooperates with a BceAB-type ABC transporter to sense and induce resistance to structurally-unrelated antimicrobial peptides of bacterial origin that all target undecaprenyl-pyrophosphate or lipid II, which are essential precursors of cell wall biosynthesis. Even though tcs01 and bceAB genes do not locate in the same gene cluster, disruption of either of them equally sensitized the bacterium to the same set of antimicrobial peptides. We show that the key function of TCS01 is to upregulate the expression of the transporter, while the latter appears the main actor in resistance. Electrophoretic mobility shift assays further demonstrated that the response regulator of TCS01 binds to the promoter region of the bceAB genes, implying a direct control of these genes. The BceAB transporter was overexpressed and purified from E. coli. After reconstitution in liposomes, it displayed substantial ATPase and GTPase activities that were stimulated by antimicrobial peptides to which it confers resistance to, revealing new functional features of a BceAB-type transporter. Altogether, this inducible defense mechanism likely contributes to the survival of the opportunistic microorganism in the human host, in which competition among commensal microorganisms is a key determinant for effective host colonization and invasive path.

7 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AJAlbin JEANNE
Albin JEANNE
TSThomas Sarazin
Thomas Sarazin
MCMagalie Charlé
Magalie Charlé
CMCatherine Moali
Catherine Moali
CFCaroline Fichel
Caroline Fichel
Stephane DedieuStephane Dedieu
Stephane Dedieu
TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2’s ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.

15 November 2019 in Toxins
Verified
Journal Article
Open access
PDF file
NFNans Florens
Nans Florens
CCCatherine Calzada
Catherine Calzada
FDFrédéric Delolme
Frédéric Delolme
APAdeline Page
Adeline Page
Fitsum Guebre-EgziabherFitsum Guebre-Egziabher
Fitsum Guebre-Egziabher
CSChristophe O. Soulage
Christophe O. Soulage
Chronic kidney disease is associated with an increased cardiovascular risk, and altered biological properties of high-density lipoproteins (HDL) may play a role in these events. This study aimed to describe the HDL proteome from non-diabetic hemodialysis patients and identify potential pathways affected by the dysregulated expression of HDL proteins. HDL were sampled from nine non-diabetic hemodialysis (HD) and eight control patients. Samples were analyzed using a nano-RSLC coupled with a Q-Orbitrap. Data were processed by database searching using SequestHT against a human Swissprot database and quantified with a label-free quantification approach. Proteins that were in at least five of the eight control and six of the nine HD patients were analyzed. Analysis was based on pairwise ratios and the ANOVA hypothesis test. Among 522 potential proteins, 326 proteins were identified to be in the HDL proteome from HD and control patients, among which 10 were significantly upregulated and nine downregulated in HD patients compared to the control patients (p < 0.05). Up and downregulated proteins were involved in lipid metabolism, hemostasis, wound healing, oxidative stress, and apoptosis pathways. This difference in composition could partly explain HDL dysfunction in the chronic kidney disease (CKD) population and participate in the higher cardiovascular risk observed in this population.

25 October 2011 in Journal of Chromatography B
Verified
Journal Article
Closed access
IZIsabelle Zanella-Cleon
Isabelle Zanella-Cleon
FDFrédéric Delolme
Frédéric Delolme
PLPhilippe Lacan
Philippe Lacan
CGCaroline Garcia
Caroline Garcia
IVIsabelle Vinatier
Isabelle Vinatier
PJPhilippe Joly
Philippe Joly